Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Certa Therapeutics Pty Ltd. has acquired Occurx Pty Ltd. in a move to strengthen its pipeline to target multiple fibrotic diseases as both companies share a focus on targeting GPR68, a defined G ...

Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...

“Chronic abdominal pain is complex because it involves multiple mechanisms, including inflammation, altered gut motility, and heightened sensitivity of the nervous system,” Muttenhalter told IE. “The ...

Breast cancer remains a leading health crisis worldwide, claiming the lives of approximately 685,000 women in 2020 alone.

This common architecture hints that GPCRs may signal by a stimulus-induced ... mutants that signal via one or the other signaling pathway may provide interesting correlations between receptor ...

Dr. Marshall is currently the chair of the UK Medical Research Council developmental pathway funding scheme ... and has now a full pipeline of novel GPCR-targeting early-stage candidates, mostly ...

A given GPCR might preferentially regulate a particular signaling pathway with specific consequences on cellular function. Furthermore, GPCRs can modulate intracellular signaling pathways with ...